What it is
Tirzepatide acts at receptors for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). That dual-receptor description identifies its pharmacologic targets; it is not itself evidence of superiority over another compound. This profile uses SURMOUNT-1 to illustrate what a large randomized human obesity study can establish, while keeping its limits visible.[3]
Research areas and evidence
SURMOUNT-1 was a phase 3 placebo-controlled study involving 2,539 adults with obesity, or overweight plus a weight-related complication, excluding diabetes. Over 72 weeks, the tirzepatide groups showed greater average weight reduction than placebo. The trial assessed weight and cardiometabolic measures under a defined protocol. It was not a head-to-head comparison with semaglutide or retatrutide, so ranking those compounds by percentages from separate trials would ignore differences in participants and design.[3]
Safety and unknowns
Gastrointestinal adverse events were the most common events reported with tirzepatide, usually mild to moderate in this trial, and adverse events caused some participants to stop treatment. That description should not be read as a guarantee of safety. The trial's duration and selection criteria constrain what it can tell us about rare harms and populations not represented. The cited publication was supported by Eli Lilly. This entry is an evidence summary rather than a complete clinical safety guide or a recommendation to obtain research-labelled material.[3]
Sources
Read the original studies and reviews. These selected sources may not include newer research.
- Phase 3 randomized human trial: SURMOUNT-1[3] Jastreboff et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM (2022).